If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"","arm_groups":[{"arm_group_label":"Individuals initiating and remaining on ABC","arm_group_description":"Individuals over the age of 16 years and in EuroSIDA cohort, who initiated and remained on ABC treatment between January 2009 and 2016, will be included in this study.","arm_type":""},{"arm_group_label":"Individuals re-starting ABC","arm_group_description":"Individuals over the age of 16 years and in EuroSIDA cohort, who re-started ABC treatment between January 2009 and 2016, will be included in this study.","arm_type":""},{"arm_group_label":"Individuals maintained on ABC","arm_group_description":"Individuals over the age of 16 years and in EuroSIDA cohort, who remained on ABC treatment between January 2009 and 2016, will be included in this study.","arm_type":""},{"arm_group_label":"Individuals discontinuing ABC due to any other reason","arm_group_description":"Individuals over the age of 16 years and in EuroSIDA cohort, who discontinued ABC due to any reasons other than HSR between January 2009 and 2016, will be included in this study.","arm_type":""},{"arm_group_label":"Individuals who started ABC from Anti retro-viral (ARV) naïve","arm_group_description":"Individuals over the age of 16 years and in EuroSIDA cohort, who started receiving ABC from ARV naïve after January 2009, will be included in this study.","arm_type":""},{"arm_group_label":"Individuals discontinuing ABC due to HSR","arm_group_description":"Individuals over the age of 16 years and in EuroSIDA cohort, who discontinued ABC due to HSR between January 2009 and 2016, will be included in this study.","arm_type":""},{"arm_group_label":"Individuals who switched to ABC for the first time","arm_group_description":"Individuals over the age of 16 years and in EuroSIDA cohort, who switched to ABC from other cART treatments for the first time during study duration between January 2009 and 2016 will be included in this study.","arm_type":""}],"assignment":"","brief_summary":"Abacavir (ABC) sulphate, a carbocyclic 2’-deoxyguanosine nucleoside analogue, was approved by the Food and Drug Administration (FDA) for the treatment of adults and children with human immunodeficiency virus (HIV) infection. It has been observed that individuals carrying human leukocyte antigen B*5701 (HLA-B*5701) are at an increased risk of ABC HSR. This retrospective study will describe changes in ABC treatment utilization and ABC HSR over time. The analysis will include data collected from the EuroSIDA cohort study of individuals above 16 years of age who have received or initiated ABC after 1 January 2009. Approximately 4500 individuals receiving ABC and 1900 initiating ABC as a part of combination antiretroviral therapy (cART) will be included in this study.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Abacavir Usage Patterns and Trends in Hypersensitivity Reactions (HSR) in the EuroSIDA cohort","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 21:20:36","criteria":"Inclusion Criteria: - Objective 1: Individuals from the EuroSIDA cohort over the age of 16 years at enrolment receiving cART (at least 3 drugs from any class, excluding ritonavir) at some point after 1 January 2009 will be included in the study. - Objective 2: All individuals to have initiated ABC after 1 January 2009 will be included in the study. Exclusion Criteria: - Individuals with drug exposure prior to EuroSIDA enrolment will not be considered for this study.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Planned","display_status_internal":"RECSTATUS_O_PLANNED","endpoint":"","enrollment":"1","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"none","id":"013937f3-bc13-54ed-ac01-b464e999e493","internal":{"content":null,"contentDigest":"9cd9ee9337cd028cfc7877f1dfbeb88e","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Objective 1: Individuals from the EuroSIDA cohort over the age of 16 years at enrolment receiving cART (at least 3 drugs from any class, excluding ritonavir) at some point after 1 January 2009 will be included in the study. - Objective 2: All individuals to have initiated ABC after 1 January 2009 will be included in the study. Exclusion Criteria: - Individuals with drug exposure prior to EuroSIDA enrolment will not be considered for this study.","interventions":[{"arm_group_label":"Individuals initiating and remaining on ABC","intervention_description":"ABC sulphate is approved for HIV treatment in adults and children. It is available in different formulations namely Ziagen, Kivexa, Trivizir and Triumeq.","intervention_name":"Abacavir","intervention_type":"drug"},{"arm_group_label":"Individuals re-starting ABC","intervention_description":"ABC sulphate is approved for HIV treatment in adults and children. It is available in different formulations namely Ziagen, Kivexa, Trivizir and Triumeq.","intervention_name":"Abacavir","intervention_type":"drug"},{"arm_group_label":"Individuals maintained on ABC","intervention_description":"ABC sulphate is approved for HIV treatment in adults and children. It is available in different formulations namely Ziagen, Kivexa, Trivizir and Triumeq.","intervention_name":"Abacavir","intervention_type":"drug"},{"arm_group_label":"Individuals discontinuing ABC due to any other reason","intervention_description":"ABC sulphate is approved for HIV treatment in adults and children. It is available in different formulations namely Ziagen, Kivexa, Trivizir and Triumeq.","intervention_name":"Abacavir","intervention_type":"drug"},{"arm_group_label":"Individuals who started ABC from Anti retro-viral (ARV) naïve","intervention_description":"ABC sulphate is approved for HIV treatment in adults and children. It is available in different formulations namely Ziagen, Kivexa, Trivizir and Triumeq.","intervention_name":"Abacavir","intervention_type":"drug"},{"arm_group_label":"Individuals discontinuing ABC due to HSR","intervention_description":"ABC sulphate is approved for HIV treatment in adults and children. It is available in different formulations namely Ziagen, Kivexa, Trivizir and Triumeq.","intervention_name":"Abacavir","intervention_type":"drug"},{"arm_group_label":"Individuals who switched to ABC for the first time","intervention_description":"ABC sulphate is approved for HIV treatment in adults and children. It is available in different formulations namely Ziagen, Kivexa, Trivizir and Triumeq.","intervention_name":"Abacavir","intervention_type":"drug"}],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":["HLA-B*5701","cART","Abacavir","EuroSIDA","HSR","HIV"],"last_follow_up_date":"07/11/2017 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"","maximum_age":null,"minimum_age":"16","minimum_age_raw":"16 Years","modified_date":"10/01/2018 22:45:42","number_of_arms":"0","observational_design":{"biospecimen_description":"NA","biospecimen_retention":"None retained","number_of_groups":"0","observational_study_design":"Cohort","patient_registry":"false","target_duration_quantity":"","target_duration_units":"","timing":"Retrospective"},"official_title":"Abacavir Usage Patterns and Trends in Hypersensitivity Reactions (HSR) in the EuroSIDA cohort","org_study_id":"206307","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Not yet recruiting - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":["United States: No Health Authority"]},"phase":"phase 4","primary_compl_date":"07/11/2017 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Number of individuals on cART including ABC","outcome_time_frame":"Approximately 7 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Evaluation of the anti retroviral therapy (ART) drugs prescribed with ABC and the use of different ABC formulations","outcome_time_frame":"Approximately 7 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Evaluation of the reasons for stopping a non-ABC based cART regimen","outcome_time_frame":"Approximately 7 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Evaluation of factors associated with starting ABC based cART","outcome_time_frame":"Approximately 7 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Evaluation of reasons for ABC discontinuation","outcome_time_frame":"Approximately 7 years","outcome_safety_issue":"True"},{"outcome_description":"","outcome_measure":"Estimation of cumulative frequency of ABC discontinuation","outcome_time_frame":"Approximately 7 years","outcome_safety_issue":"True"},{"outcome_description":"","outcome_measure":"Number of incidences of ABC discontinuation","outcome_time_frame":"Approximately 7 years","outcome_safety_issue":"True"},{"outcome_description":"","outcome_measure":"Comparison of key characteristics of individuals who remain on ABC and individuals who discontinue ABC","outcome_time_frame":"Approximately 7 years","outcome_safety_issue":"True"},{"outcome_description":"","outcome_measure":"Identification of factors associated with ABC discontinuation","outcome_time_frame":"Approximately 7 years","outcome_safety_issue":"True"}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["N/A"]},"start_date":"02/23/2017 00:00:00","study_type":"Observational","therapeutic_area":"","citations":[],"is_section_801":null}},"pageContext":{"studyId":"206307"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}